

S L2 OR CS 747?

98108 CS
86 CSES
98189 CS

(CS OR CSES)

TERM '747?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED

You have entered a truncated stem which occurs in too many terms.
Make the stem longer and try again. For example, if your original
term was 'degr?' to search for variations and the abbreviation for
'degradation', you could replace it with the expression '(degrdn OR
degrad?)'. If your search term was numeric, e.g., 'C>5', reduce the
size of the range.

=> s l1 <> or cs 747

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.96	34.52

FILE 'REGISTRY' ENTERED AT 10:21:43 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1-
L4 SEL L1 1- CHEM : 3 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.11	46.63

FILE 'CAPLUS' ENTERED AT 10:21:44 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

S L4 OR CS 747

98108 CS
86 CSES
98189 CS
(CS OR CSES)
3395 747
23 CS 747
(CS(W)747)

L6 108 L5 OR CS 747

=> s 16 and pd <=2001
21909579 PD <=2001
(PD<=20019999)

L7 8 L6 AND PD <=2001

=> d ibib abs hitstr 1-8

L7 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:880552 CAPLUS

DOCUMENT NUMBER: 137:56780

TITLE: CS-747 and R-99224: platelet
antiaggregatory P2T antagonists

AUTHOR(S): Doggrell, S. A.; Mealy, N. E.; Castaner, J.

CORPORATE SOURCE: Department of Physiology and Pharmacology, The
University of Queensland, Brisbane, 4072, Australia

SOURCE: Drugs of the Future (2001), 26(9), 835-840

CODEN: DRFUD4; ISSN: 0377-8282

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review discusses the synthesis, pharmacol. actions, pharmacokinetics and
clin. studies of CS-747 and R-99224. CS-
747 is a novel prodrug-type antiplatelet agent acting as a P2TAC
receptor antagonist via its active metabolite R-99224.

IT 150322-43-3, CS 747

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(prodrug CS-747 and its metabolite R-99224:
platelet aggregation inhibition)

RN 150322-43-3 CAPLUS

CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-
cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:283949 CAPLUS

DOCUMENT NUMBER: 134:311218

TITLE: Synthesis and use of heterocyclic sodium/proton
exchange inhibitors

INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu,
Khehyong; Atwal, Karnail S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002 <--
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870	B1	20050503	US 2000-669298	20000925
CA 2388813	A1	20010419	CA 2000-2388813	20001002 <--
EP 1224183	A2	20020724	EP 2000-968723	20001002
EP 1224183	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014725	A	20030617	BR 2000-14725	20001002
HU 2003000195	A2	20030728	HU 2003-195	20001002
HU 2003000195	A3	20030929		
JP 2003527331	T	20030916	JP 2001-530325	20001002
NZ 517668	A	20040924	NZ 2000-517668	20001002
AT 314364	T	20060115	AT 2000-968723	20001002
ES 2254236	T3	20060616	ES 2000-968723	20001002
IN 2002MN00354	A	20050318	IN 2002-MN354	20020322
ZA 2002002479	A	20040727	ZA 2002-2479	20020327
MX 2002PA03626	A	20030922	MX 2002-PA3626	20020410
NO 2002001717	A	20020610	NO 2002-1717	20020411
US 20050137216	A1	20050623	US 2005-46993	20050131
US 7326705	B2	20080205		
PRIORITY APPLN. INFO.:			US 1999-158755P	P 19991012
			US 2000-669298	A3 20000925
			WO 2000-US27461	W 20001002

OTHER SOURCE(S): MARPAT 134:311218


GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR⁵, where R⁵ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R¹ is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R², R³ and R⁴ are any of the groups set out for R¹ and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R¹ is preferably aryl or heteroaryl] are claimed.

Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α -chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β -adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 150322-43-3, CS 747
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceuticals containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
 RN 150322-43-3 CAPLUS
 CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)




L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:114128 CAPLUS
 DOCUMENT NUMBER: 134:290186
 TITLE: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747
 AUTHOR(S): Sugidachi, Atsuhiko; Asai, Fumitoshi; Yoneda, Kenji; Iwamura, Ryo; Ogawa, Taketoshi; Otsuguro, Ken-Ichi; Koike, Hiroyuki
 CORPORATE SOURCE: Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Tokyo, 140-8710, Japan
 SOURCE: British Journal of Pharmacology (2001), 132(1), 47-54
 CODEN: BJPCBM; ISSN: 0007-1188
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB CS-747 is a novel thienopyridine-type platelet ADP inhibitor which lacks in vitro activity. This study examined pharmacol. profiles of R-99224, a hepatic metabolite of CS-747. R-99224 produced a concentration-dependent inhibition of in vitro platelet aggregation in washed human platelets (0.03-1 μ g ml⁻¹), which was relatively specific to ADP compared to collagen and thrombin. R-99224 (0.1-3 μ g ml⁻¹) also elicited a similar inhibition of ADP-induced aggregation in rat platelets. The inhibition by R-99224 (10 μ g ml⁻¹) persisted even after platelets were washed three times. I.v. injection of R-99224 (0.1-3 mg kg⁻¹) to rats resulted in a dose-dependent inhibition of

ex vivo ADP-induced platelet aggregation. R-99224 (0.1-100 μ M) decreased binding of [3H]-2-methylthio-ADP ([3H]-2-MeS-ADP), a stable ligand for platelet ADP receptors, to washed human platelets. The inhibition by R-99224 reached a plateau at a concentration of 3 μ M (1.4 μ g ml⁻¹), but complete inhibition was not achieved even at the highest concentration used (100 μ M). R-99224 (10 μ M) in combination with ARL-66096 (0.3 μ M), an ATP analog-type Gi-linked P2T receptor antagonist, produced no addnl. inhibition of [3H]-2-MeS-ADP binding. In contrast, [3H]-2-MeS-ADP binding was completely abolished by R-99224 (10 μ M) in combination with A3P5PS (300 μ M), a selective P2Y1 antagonist, suggesting that R-99224 selectively binds to the Gi-linked P2T receptor. R-99224 (0.01-3 μ g ml⁻¹) inhibited ADP-induced [125I]-fibrinogen binding to human platelets in a concentration-dependent manner. R-99224 (0.1-1 μ g ml⁻¹) also inhibited the ADP-induced decrease in cAMP levels in PGE1-stimulated platelets, whereas the agent did not affect ADP (10 μ M)-induced Ca²⁺ mobilization. These findings suggest that R-99224 is a selective and irreversible antagonist of Gi-linked P2T receptors and that R-99224 is a responsible mol. for in vivo actions of CS-747.

IT 150322-43-3, CS-747
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antiplatelet action of R-99224, active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747)


RN 150322-43-3 CAPLUS
 CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:288118 CAPLUS
 DOCUMENT NUMBER: 133:187474
 TITLE: CS-747, a new platelet ADP receptor antagonist
 AUTHOR(S): Asai, Fumitoshi; Konse, Tomonori; Sugidachi, Atsuhiko; Ikeda, Toshihiko; Sanbuissho, Atsushi; Hirota, Takashi
 CORPORATE SOURCE: Pharmacology and Molecular Biology Research Laboratories, Product Development Laboratories, SANKYO CO., LTD., Tokyo, 140-8710, Japan
 SOURCE: Annual Report of Sankyo Research Laboratories (1999), 51, 1-44
 CODEN: ASRLEC; ISSN: 1341-741X
 PUBLISHER: Sankyo Co., Ltd., Research Institute
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 29 refs. on physicochem. properties and pharmacol. of the title antiplatelet agent.

IT 150322-43-3, CS 747
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (physicochem. properties and pharmacol. of platelet ADP receptor antagonist CS-747)
 RN 150322-43-3 CAPLUS
 CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:248653 CAPLUS

DOCUMENT NUMBER: 133:53438

TITLE: The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

AUTHOR(S): Sugidachi, Atsuhiko; Asai, Fumitoshi; Ogawa, Taketoshi; Inoue, Teruhiko; Koike, Hiroyuki

CORPORATE SOURCE: Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Tokyo, 140-8710, Japan
 SOURCE: British Journal of Pharmacology (2000), 129(7), 1439-1446

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group


DOCUMENT TYPE: Journal

LANGUAGE: English

AB CS-747 is a novel antiplatelet agent that generates an active metabolite, R-99224, in vivo. CS-747 itself was totally inactive in vitro. This study examined in vivo pharmacol. profiles of CS-747 after single oral administration to rats. Orally administered CS-747 (0.3-10 mg kg⁻¹) partially but significantly decreased [³H]-2-methylthio-ADP binding to rat platelets. CS-747 (3 mg kg⁻¹, p.o.) treatment neutralized ADP-induced decreases of cAMP concns. induced by prostaglandin E₁, suggesting that metabolites of CS-747 interfere with Gi-linked P₂T receptor. CS-747 (0.3 and 3 mg kg⁻¹, p.o.) markedly inhibited ex vivo washed platelet aggregation in response to ADP but not to thrombin. CS-747 also exhibited a marked inhibition of ADP-induced ex vivo platelet aggregation in PRP with a rapid onset (<0.5 h) and long duration (>3 days) of action (ED₅₀ at 4 h = 1.2 mg kg⁻¹). R-99224 (IC₅₀ = 45 μM) inhibited in vitro PRP aggregation in a concentration-related manner. CS-747 prevented thrombus formation in a dose-related manner with an ED₅₀ value of 0.68 mg kg⁻¹. CS-747 was more potent than clopidogrel (6.2 mg kg⁻¹) and ticlopidine (>300 mg kg⁻¹). CS-747, clopidogrel, and ticlopidine prolonged the bleeding time.

The order of potency of these agents in this activity was the same as that in antiaggregatory and antithrombotic activities. These findings indicate that CS-747 is an orally active and a potent antiplatelet and antithrombotic agent with a rapid onset and long duration of action, and warrants clin. evaluations of the agent.

IT 150322-43-3, CS 747
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. profile of oral CS-747, antiplatelet agent with platelet ADP receptor antagonist properties)
 RN 150322-43-3 CAPLUS
 CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:42276 CAPLUS
 DOCUMENT NUMBER: 128:93213
 TITLE: Novel medicinal compositions of hydropyridines
 INVENTOR(S): Asai, Fumitoshi; Ogawa, Taketoshi; Inoue, Teruhiko
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan; Ube Industries, Ltd.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9749397	A1	19971231	WO 1997-JP2173	19970624 <--
W: AU, CA, CN, CZ, HU, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9731915	A	19980114	AU 1997-31915	19970624 <--
JP 10310586	A	19981124	JP 1997-167291	19970624 <--
PRIORITY APPLN. INFO.:			JP 1996-166126	A 19960626
			JP 1997-54587	A 19970310
			WO 1997-JP2173	W 19970624

OTHER SOURCE(S): MARPAT 128:93213


AB The invention relates to compns. containing as the active ingredient 4,5,6,7-tetrahydrothieno[3,2-c]pyridines represented by the following general formula : R1-CH(R2)-R3 or pharmacol. acceptable salts thereof which have an excellent effect of inhibiting the progression of arteriosclerosis and a low toxicity and, therefore, are highly useful as remedies or preventives for arteriosclerosis. In said formula, R1 represents optionally substituted phenyl; R2 represents H, alkoxycarbonyl or optionally substituted aliphatic acyl; and R3 represents optionally

substituted 4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl.
 IT 150322-43-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel medicinal compns. of antiarteriosclerotic hydropyridines)
 RN 150322-43-3 CAPLUS
 CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:431428 CAPLUS
 DOCUMENT NUMBER: 125:86871
 TITLE: Preparation of silyloxytetrahydrothienopyridines as pharmaceutical intermediates
 INVENTOR(S): Ataka, Kikuo; Miyata, Hiroyuki; Kono, Masahiko; Yokota, Naoyuki; Yamamoto, Yasuhito
 PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611203	A1	19960418	WO 1995-JP2023	19951004 <--
W: CA, FI, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 785205	A1	19970723	EP 1995-933605	19951004 <--
EP 785205	B1	20020417		
R: DE, FR, GB, IT				
JP 3840662	B2	20061101	JP 1996-512474	19951004
US 5874581	A	19990223	US 1997-817001	19970331 <--
PRIORITY APPLN. INFO.:			JP 1994-244141	A 19941007
			WO 1995-JP2023	W 19951004
OTHER SOURCE(S):		MARPAT 125:86871		
GI				



AB The tile compds. I [R1 - R3 = alkyl, aryl] are claimed. A mixture of

tetrahydrothienopyridine II p-toluenesulfonic acid salt, triethylamine, and tert-butyldimethylchlorosilane in acetonitrile was stirred at room temperature for 6 h and then kept at room temperature for 12 h to give, after workup,

I [R1 = R2 = methyl; R3 = tert-butyl].


IT 150322-43-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of silyloxytetrahydrothienopyridines as pharmaceutical intermediates)

RN 150322-43-3 CAPLUS

CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:8583 CAPLUS

DOCUMENT NUMBER: 120:8583

ORIGINAL REFERENCE NO.: 120:1889a,1892a

TITLE: Preparation of substituted hydrothienopyridine derivatives having antithrombotic activity

INVENTOR(S): Koike, Hiroyuki; Asai, Fumitoshi; Sugidachi, Atsuhiko; Kimura, Tomio; Inoue, Teruhiko; Nishino, Shigeyoshi; Tsuzaki, Yasunori

PATENT ASSIGNEE(S): Japan

SOURCE: Can. Pat. Appl., 180 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CA 2077695	A1	19930310	CA 1992-2077695	19920908 <--
CA 2077695	C	20020820		
ZA 9206784	A	19930329	ZA 1992-6784	19920907 <--
FI 101150	B	19980430	FI 1992-4002	19920907 <--
FI 101150	B1	19980430		
NO 9203484	A	19930310	NO 1992-3484	19920908 <--
NO 303733	B1	19980824		
AU 9222847	A	19930318	AU 1992-22847	19920908 <--
AU 656798	B2	19950216		
JP 06041139	A	19940215	JP 1992-239083	19920908 <--
US 5288726	A	19940222	US 1992-941676	19920908 <--
IL 103098	A	19960514	IL 1992-103098	19920908 <--
RU 2089553	C1	19970910	RU 1992-5052879	19920908 <--
EP 542411	A2	19930519	EP 1992-308180	19920909 <--
EP 542411	A3	19930721		
EP 542411	B1	19980812		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

CN 1074446	A	19930721	CN 1992-111584	19920909 <--
CN 1041730	B	19990120		
HU 66195	A2	19941028	HU 1992-2888	19920909 <--
HU 218785	B	20001228		
AT 169627	T	19980815	AT 1992-308180	19920909 <--
KR 148023	B1	19980817	KR 1992-16620	19920909 <--
ES 2122984	T3	19990101	ES 1992-308180	19920909 <--
CZ 287181	B6	20001011	CZ 1992-2784	19920909 <--
US 5436242	A	19950725	US 1993-161046	19931201 <--
HU 9500535	A3	19951030	HU 1995-535	19950629 <--
CN 1217186	A	19990526	CN 1998-109220	19980516 <--
CN 1107502	B	20030507		

PRIORITY APPLN. INFO.:

JP 1991-227875	A	19910909
JP 1992-138529	A	19920529
US 1992-941676	A3	19920908
CS 1992-2784	A	19920909

OTHER SOURCE(S): MARPAT 120:8583
GI




AB Title compds. I (R1 = H, C1-4 alkyl, halo, halo-C1-4-alkyl, HO, (halo)-C1-4-alkoxy, halo-C1-4-alkylthio, etc.; R2 = (substituted) C1-10 alkanoyl, -C3-6 alkenoyl, -C4-8 cycloalkylcarbonyl, -Bz, 5,6-dihydro-1,4,2-dioxazin-3-yl; R3 = H, HO, (substituted) C1-4 alkoxy, aralkyloxy, C1-18 alkanoyloxy, C3-6 alkenoyloxy, C4-8 cycloalkylcarbonyloxy, arylcarbonyloxy, etc.; Y = NH, O, S; n = 1-5) and a salt thereof, are prepared 5-(α -Cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7 α -hexahydrothieno[3,2-c]pyridine (preparation given) in DMF and Ac2O was added to NaH to give I (R1m = 2-F, R2 = cyclopropylcarbonyl, R3 = 2-AcO, Y = S) (II). Antithrombotic activity was measured by inhibition of blood platelet aggregation whereby II at 1 mg/kg showed 100% inhibition.

IT 150322-43-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antithrombotic)

RN 150322-43-3 CAPLUS

CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (CA INDEX NAME)



=>